XML 109 R91.htm IDEA: XBRL DOCUMENT v3.23.4
STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) - $ / shares
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2021
Obagi Cosmeceuticals      
Weighted Average Grant Date Fair Value per Share      
Exercised, weighted average grant date fair value (in dollars per share)   $ 0 $ 0
Restricted stock | Waldencast plc      
Shares      
Outstanding, beginning balance (in shares) 0    
Granted (in shares) 3,173,364    
Vested (in shares) (370,945)    
Forfeited (in shares) 0    
Outstanding, ending balance (in shares) 2,802,419 0  
Weighted Average Grant Date Fair Value per Share      
Outstanding beginning balance, weighted average grant date fair value (in dollars per share) $ 0    
Granted, weighted average grant date fair value (in dollars per share) 9.16    
Vested, weighted average grant date fair value (in dollars per share) 10.00    
Forfeited, weighted average grant date fair value (in dollars per share) 0    
Outstanding ending balance, weighted average grant date fair value (in dollars per share) $ 9.16 $ 0  
Restricted Stock Units (RSUs)      
Weighted Average Grant Date Fair Value per Share      
Granted, weighted average grant date fair value (in dollars per share)   $ 38.90 $ 38.68
Restricted Stock Units (RSUs) | Obagi Cosmeceuticals      
Shares      
Outstanding, beginning balance (in shares) 234,842 243,307 0
Granted (in shares)   1,754 243,307
Vested (in shares)   0 0
Exercised (in shares)   0 0
Forfeited (in shares)   10,219 0
Outstanding, ending balance (in shares)   234,842 243,307
Weighted Average Grant Date Fair Value per Share      
Outstanding beginning balance, weighted average grant date fair value (in dollars per share) $ 38.90 $ 38.68 $ 0
Granted, weighted average grant date fair value (in dollars per share)   68.19 38.68
Vested, weighted average grant date fair value (in dollars per share)   0 0
Forfeited, weighted average grant date fair value (in dollars per share)   38.68 0
Outstanding ending balance, weighted average grant date fair value (in dollars per share)   $ 38.90 $ 38.68